Therefore, drug combination appears to be the most attractive area of pre-clinical research, e.g., abraxane was successfully used with trastuzumab and carboplatin in first-line therapy for advanced HER-2 positive breast cancer [12] and docetaxel with pertuzumab and trastuzumab in first-line treatment for HER2-positive metastatic breast cancer [13]. The gene discussed is ERBB2; the disease is breast cancer.